Peripheral Blood Stem Cell Transplantation
14
3
4
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
2 terminated out of 14 trials
66.7%
-19.8% vs benchmark
7%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
Eltrombopag for Peripheral Blood Stem Cell Harvest
Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma
Incidence and Factors Associated With the Development and Severity of Oral Mucositis
KRN125 for Mobilization of Hematopoietic Stem Cells
Ruxolitinib and Decitabine for High Risk Hematological Malignancies
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies
Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD